Recent analyst notes place AMLX stock forecast at a 12-month price target of $23 based on pipeline progress and expanding revenue forecasts. Market watchers highlight resilience amid broader Nasdaq biotech volatility. Already, Relyvrio has put the company in the black. It’s generated three consecutive profitable quarters and projects a 105% earnings increase in the next 12 months. On the top line, revenue continues to show sequential growth. In its last quarter, revenue broke the $100 million mark. Amarin Corporation plc (AMRN) is a biopharmaceutical company focused on improving cardiovascular health with its flagship product, Vascepa. Vascepa is a prescription omega-3 treatment designed to help reduce cardiovascular risk in patients with high triglycerides. The company’s growth is driven by e AMLX stock forecast for mid-2024 trends toward modest gains, with technical charts showing strong support levels around $18.